Cargando…
Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches
More than 15 years ago, imatinib entered into the clinical practice as a “magic bullet”; from that point on, the prognosis of patients affected by chronic myeloid leukemia (CML) became comparable to that of aged-matched healthy subjects. The aims of treatment with tyrosine kinase inhibitors (TKIs) a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742705/ https://www.ncbi.nlm.nih.gov/pubmed/31555590 http://dx.doi.org/10.3389/fonc.2019.00833 |